Dr. Sophie Dobiasch is a clinician scientist and Junior Group Leader at the Institute of Radiation Medicine (IRM), Helmholtz Munich, and the Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich (TUM). Since 2015, she has focused on translational research in personalized radiooncology for pancreatic cancer, integrating clinical practice and experimental studies. Education: Medical doctor (MD) at Ruprecht-Karls University Heidelberg (2008-2015). Her research explores mechanisms of radioresistance in pancreatic cancer, leveraging targeted therapies, cytotoxic agents, and herbal substances. She employs advanced techniques such as small animal imaging and high-precision irradiation to bridge lab discoveries with clinical applications. Recent publications highlight her work on phosphoproteomic analysis, radiosensitization using Curcumin, and DNA repair pathways in pancreatic cancer. These studies align with broader themes in radiation oncology, molecular biology, and translational medicine. Scientific Awards: Award for 2nd best young investigator talk (2018). Dobiasch collaborates with networks including the German Consortium for Translational Cancer Research (DKTK), SFB 1321, and the European Pancreatic Cancer Center. Her intercultural experience spans stays in Japan, Great Britain, India, and Nepal.
David Lim is an Associate Professor at the University of Technology Sydney (UTS), affiliated with the IMPACCT department. He specializes in primary healthcare for vulnerable populations, including Indigenous Australians, rural communities, and individuals with chronic conditions. His research focuses on policy impacts, rural healthcare systems, and healthcare equity. Lim has secured over $10 million in grants and his work influences global health policies such as WHO guidelines and OECD frameworks. He currently holds roles including HDR Coordinator at IMPACCT and leads the Evidence, Implementation, Evaluation & Policy theme at INSIGHT Digital, Virtual and AI in Health Collaborative. His research has directly shaped Australian pharmacy policies and international frameworks, including contributions to biosimilar initiatives and disaster management protocols. Lim’s career includes over a decade of rural healthcare experience, emphasizing collaborative partnerships to address systemic inequities. Key funded projects include telemedicine development for underserved areas and evaluations of chronic disease self-management programs. Lim’s expertise spans translational research, implementation science, and health policy analysis. His recent work addresses rural general practice capacity, Indigenous youth mental health, and palliative care innovations. He serves as a Guest Editor for Public Health: Rural Health Services Research and maintains active collaborations via LinkedIn, Google Scholar, and ResearchGate.
Dr. Zui Pan is a Professor at The University of Texas at Arlington (UTA) in the College of Nursing and Health Innovation, with additional appointments in the Department of Biology, Bioengineering, and Kinesiology. She has been at UTA since 2016, initially as an Associate Professor and promoted to Professor in 2021. Prior to UTA, she held academic positions at The Ohio State University, Rutgers-Robert Wood Johnson Medical School, and UMDNJ. Dr. Pan earned her BS and MS in Biophysics from Nankai University in China, followed by a PhD in Biophysics from the Institute of Biophysics at the Chinese Academy of Sciences. She completed postdoctoral training in the Department of Physiology and Biophysics at Case Western Reserve University. Dr. Pan's research focuses on calcium and zinc signaling in esophageal cancer, muscle, and heart diseases. Her work aims to understand the cellular mechanisms underlying dysregulated calcium signals to provide insights for disease prevention and treatment. She has published over 100 articles in prestigious journals including Nature, Nature Cell Biology, and Nature Communications, with research featured in Newsweek, Reader's Digest, and ScienceDaily. Analysis of Dr. Pan's recent publications reveals a strong focus on calcium signaling pathways in cancer biology, particularly esophageal cancer. Her work integrates molecular biology, physiology, and mathematical modeling to understand store-operated calcium entry mechanisms and their role in cancer progression. Recent publications also show expanding interests in cardiac physiology, tissue engineering, and translational applications of her basic research findings. Dean's Research Mentoring Award, UTA College of Nursing and Health Innovation (2024) Faculty Scholarship Mentor Award, UTA College of Nursing and Health Innovation (2024) Interdisciplinary Research Award, UTA (2024) R15 Research Award, National Institutes of Health (2023) Senior Member, National Academy of Inventors (2020) Texas STARS Award (2016) Dr. Pan has mentored numerous students across multiple disciplines, serving as Dissertation Committee Chair for PhD students in Nursing, Kinesiology, and related programs. Her laboratory has received over $3 million in research funding from NIH (R01, R15, S10 awards), the American Diabetes Association, and other sources. She actively collaborates with researchers across multiple departments and institutions. Dr. Pan directs a research laboratory focused on calcium signaling mechanisms, with specialized equipment including a Confocal Microscopy and Cell Imaging Core. Her team includes postdoctoral researchers, graduate students, and undergraduate researchers working collaboratively on projects spanning cancer biology, cardiac physiology, and muscle regeneration.
Karen Anderson, PhD, is a Professor of Pharmacology and Molecular Biophysics and Biochemistry at Yale School of Medicine. She serves as Co-Leader of the Developmental Therapeutics Program at Yale Cancer Center and Co-Director of the Therapeutics/Chemotherapy Program. Her research focuses on mechanistic enzymology and structure-based drug design to develop therapies for cancer, infectious diseases (e.g., HIV/AIDS), and antimicrobial targets. She has trained over 50 students across undergraduate, graduate, and postdoctoral levels. Educational Background: PhD from Ohio State University (1982), Senior Research Specialist at Monsanto Co. (1989). Research Interests: HIV reverse transcriptase mechanisms, antiviral agents, drug resistance, enzyme inhibitors for cancer and infectious diseases, and translational drug development. Key targets include KDO8P synthase (antibacterial), TS-DHFR (antiparasitic), and tyrosine kinase inhibitors (cancer). Awards & Honors: Dean's Young Faculty Award (1991), Yale Cancer Breast Cancer Initiative Award (1996), Gordon Research Conference leadership (2000-2001), and multiple Monsanto Research Achievement Awards (1985-1989). Grants & Collaborations: Leads interdisciplinary teams at Yale Cancer Center and collaborates with researchers like William Jorgensen on drug design. Her lab's work includes developing synergistic therapies for bladder cancer and alternatives to Paxlovid for SARS-CoV-2. Labs & Teams: Anderson Lab at Yale, part of the Structural Biology and Virology Laboratories programs. Active in initiatives like the Yale-UPR HIV Research Collaboration.
Dr. Jason K. Molitoris serves as Associate Professor and UMMC Medical Director in the Department of Radiation Oncology at the University of Maryland, based at the Marlene and Stewart Greenebaum Comprehensive Cancer Center. His clinical expertise spans genitourinary, gastrointestinal, central nervous system, and hematologic malignancies, with a focus on implementing advanced radiation technologies to optimize treatment efficacy and minimize side effects. His educational background includes: Bachelor of Science in Biology, Summa cum laude, Phi Beta Kappa, The College of William and Mary MD/PhD through Medical Scientist Training Program, Case Western Reserve University School of Medicine (Alpha Omega Alpha) Internal Medicine Internship, Greater Baltimore Medical Center Radiation Oncology Residency and Chief Residency, University of Maryland Medical Center Dr. Molitoris' research integrates basic science (cell death mechanisms in leukemia/lymphoma) with clinical applications of proton therapy, brachytherapy, and hyperthermia. His work emphasizes novel radiosensitization approaches, clinical trial development, and translational studies to improve outcomes in prostate, gastrointestinal, and CNS cancers while reducing treatment toxicity. Analysis of his 15 most recent publications reveals a strong clinical outcomes focus across brain metastases, lung, breast, and prostate cancers. His work frequently utilizes multi-institutional collaborations and national databases to evaluate prognostic factors, treatment patterns, and advanced technologies like proton therapy, with consistent emphasis on balancing efficacy with quality-of-life preservation. His awards include: Lynn Sage Breast Cancer Symposium Scholar Award RSNA Roentgen Resident/Fellow Research Award International Congress for Hyperthermic Oncology New Investigator Travel Award ASCO/AACR Research Fellow designation American Radium Society Travel Grant Award ASTRO Advocacy Day Travel Grant H.E.R.O. Award nomination University of Maryland Chief Resident distinction Dr. Molitoris actively develops clinical trials through AACR/ASCO workshops and mentors residents, though specific grant details and student advisees aren't documented. His national presentations reflect leadership in radiation oncology innovation, particularly in thermal therapy and proton applications. He operates within the Marlene and Stewart Greenebaum Comprehensive Cancer Center ecosystem, collaborating with multidisciplinary teams across the Maryland Proton Treatment Center and leveraging institutional resources for translational research in advanced radiation modalities.
Mark Oldham is Professor of Radiation Oncology and Professor of Physics at Duke University, where he also serves as Director of the Duke Medical Physics MS/PhD Graduate Program and is a Member of the Duke Cancer Institute. His academic career spans over three decades with progressive appointments from Instructor to full Professor in Radiation Oncology. Dr. Oldham received his Ph.D. from Newcastle University (United Kingdom) in 1991. His research interests focus on innovative approaches to radiation therapy, particularly FLASH radiation therapy using the Duke High Intensity Gamma Source (HIGS), radiation and immunotherapy utilizing mini-grids, Radiation Therapy Enhanced by Cherenkov photo-Activation (RECA), and comprehensive 3D dosimetry systems. His work has been recognized with multiple Paper of the Year awards from SEAAPM and the prestigious Farrington Daniel Award from AAPM. His recent publications demonstrate a strong focus on 3D dosimetry systems, radiation therapy verification techniques, and novel cancer treatment approaches. His research integrates advanced dosimetry methods with innovative radiation therapy techniques to improve cancer treatment outcomes. His work on polymer gel dosimetry, optical CT scanning, and radiation-immunotherapy combinations represents cutting-edge developments in the field. Dr. Oldham's scientific achievements have been recognized through multiple awards including the Paper of the Year (2018, 2017), Farrington Daniel Award (2016, 2002), Excellence in Teaching (2014), Excellence in Mentoring (2011), and Fellow of the AAPM (2010). He has also received the Director's Award for Exemplary Service multiple times. As a principal investigator and co-investigator, Dr. Oldham has secured significant research funding from the National Institutes of Health, National Institute of Dental and Craniofacial Research, and Ian's Friends Foundation. His current research portfolio includes exploring synthetic lethality with high energy electron FLASH radiation beams, super-FLASH therapy for pediatric brain tumors, and radiation protection mechanisms. He serves on the Board of Directors of the American Association of Medical Physics and has made significant contributions to medical physics education through his leadership of Duke's Medical Physics Graduate Program.
Yasemin KAPTAN is an Assistant Professor at Beykent University in the Faculty of Engineering and Architecture, Department of Chemical Engineering. She actively contributes to research in biomaterials, drug delivery systems, and enzymatic polymer synthesis through publications in SCI/SCI-Expanded journals. Research Focus: Her work emphasizes Development of dual-functioning materials for targeted drug delivery and radiosensitization Biocomposite hydrogels for wound healing applications Enzymatic synthesis of biodegradable polymers like polycaprolactone Surface modification of silica-based supports for enzyme immobilization Controlled release mechanisms in pH-responsive systems Nanohybrid materials for pharmaceutical applications Publication Trends: Her research spans materials science, biomedical engineering, and chemical engineering, with recent advancements in metal-organic frameworks (MOFs) and chitosan-based composites. Earlier work focuses on optimizing enzyme immobilization protocols and polymer-silica hybrids. Academic Duties: She teaches core chemical engineering courses such as Thermodynamics, Process Dynamics and Control, Mass Transfer, and Heat Transfer, reflecting her expertise in both theoretical and applied aspects of the field.
University Medical Center Hamburg-EppendorfGermany
Manfred Jücker is a Professor at the Institute of Biochemistry and Signal Transduction within the University Medical Center Hamburg-Eppendorf (UKE) . His research focuses on phosphoinositide signaling pathways , particularly the PI3K/AKT/mTOR network , and their roles in cancer progression and leukemia pathogenesis . Jücker investigates how Akt isoforms differentially regulate metastasis , drug resistance , and cell survival in tumors like hepatocellular carcinoma , breast cancer , and colorectal cancer . Recent publications highlight his work on SHIP1 phosphatase in hematopoietic malignancies , targeted kinase inhibition in AML , and metabolic reprogramming via AKT isoform regulation . His team uses in vitro tumor models , xenotransplantation , and phosphoproteomics to explore novel therapeutic approaches. Jücker collaborates extensively with clinicians and researchers in oncology , immunology , and translational medicine , contributing to drug development strategies and personalized cancer therapy . Key projects include reducing animal experiments through in vitro tumoroids and analyzing CYTL1 as a treatment target in elderly AML patients.
Tomasz Powrózek is an Associate Professor at the Department of Human Physiology, Faculty of Medical Sciences, Medical University of Lublin. He holds an MD, PhD, and DSc, and is actively engaged in research and teaching in the field of medical sciences, with a strong focus on lung cancer and molecular genetics. His research interests include lung cancer , genetic polymorphisms , drug resistance , gene expression , and oncogenesis . These are reflected in his extensive publication record and research tag cloud, which highlights terms such as 'non-small cell lung cancer,' 'DNA,' 'smoking,' and 'prognosis.' His work bridges clinical medicine and molecular biology, contributing to translational oncology. The analysis of his recent publications reveals a consistent focus on the molecular mechanisms underlying lung cancer, particularly in the areas of genetic susceptibility, epigenetic regulation, and treatment resistance. His studies often involve human subjects and utilize molecular techniques to identify biomarkers and prognostic factors. There is a strong emphasis on personalized medicine and improving clinical outcomes. Scientific Awards and Achievements: Achievement in research (1 documented) Advising and Grants: Dr. Powrózek has promoted 4 doctoral theses, indicating active mentorship in graduate education. He has participated in at least one research project, contributing to funded academic inquiry in his field. Labs and Research Teams: While specific lab names are not mentioned, his affiliation with the Department of Human Physiology suggests involvement in a research team focused on molecular and physiological aspects of disease, particularly cancer biology and human pathophysiology.
Ina Kurth is the Division Head of the Service Unit for Radiopharmaceuticals and Morszeck Preclinical Trial Unit (PCTU) at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. She also serves as Deputy Head and Laboratory Head of the Division of Radiation Oncology/Radiobiology. Dr. Kurth’s research focuses on preventing therapy resistance in tumors, particularly radioresistance, with a translational emphasis on molecular markers bridging clinical and experimental research. Education: 1999–2005: MSc Biology (Diploma), Friedrich Schiller University Jena, Thesis: Cell adhesion dynamics and force development. 2005–2011: PhD, Technical University of Dresden, Dissertation: Hematopoietic stem cell differentiation in microcavity systems. Research Interests: Radiobiology, radiation oncology, therapy resistance mechanisms, biomarker translation, head and neck cancer biology. Her work integrates preclinical models, transcriptomics, and epigenetic analyses to develop strategies for overcoming radioresistance. Key Contributions: Built the joint radiooncological/radiobiological laboratory (2018) and PCTU (2022). Holds a patent on biomaterial systems for stem cell regulation (2008). Her recent work emphasizes single-cell transcriptomics and AI-driven imaging for precision oncology. Teaching & Leadership: Coordinates the Cancer Biology Master’s program at DKFZ, led the 2022 Summer School in Medical Physics, and supervised 10 student theses. Active in facility governance roles at DKFZ and DEGRO. Labs & Initiatives: Oversees the PCTU and radiopharmaceutical service unit, advancing translational research infrastructure in oncology.
Adeboye Adejare is a Professor in the Department of Pharmaceutical Sciences. His research focuses on designing and synthesizing small organic molecules to study neurodegeneration, particularly in stroke and Alzheimer’s Disease, with an emphasis on NMDA receptor antagonists and γ-secretase inhibitors. His work also explores in vitro drug absorption models, blood-brain barrier penetration, and fluoroaromatic compounds. Funding for his research comes from the National Institutes of Health (NIH), the Office of Naval Research (ONR), and pharmaceutical companies. Education: BS, University of Iowa MS, University of Iowa PhD in Medicinal Chemistry, Ohio State University His research has led to over 30 publications, a patent, and more than 80 presentations at national and international conferences. Students from his group have earned graduate degrees (MS and PhD) and now work in academia and the pharmaceutical industry. He has contributed to book chapters, including edits for the 22nd Edition of Remington: The Science and Practice of Pharmacy . Labs & Teams: Pharmacology and Toxicology Center
Dr. James Laird is an Assistant Professor of Therapeutic Radiology at Yale School of Medicine. He sees patients at Smilow Cancer Hospital in Waterford and is affiliated with Yale Cancer Center and Yale Medicine. His clinical practice focuses on treating thoracic, head and neck, gastrointestinal, skin, and gynecologic malignancies using advanced radiotherapy techniques. Dr. Laird received his BA from Columbia University in 2013, followed by his MD from New York University School of Medicine in 2018, where he was inducted into the Alpha Omega Alpha honor society and named the highest performing student in the preclinical curriculum. He completed his internship at Lenox Hill Hospital in 2019 and his residency in radiation oncology at Yale New Haven Hospital in 2023, serving as Chief Resident for the 2022-2023 academic year. Dr. Laird's research primarily focuses on the role of local treatments in oligometastatic cancer, aiming to improve patient outcomes through innovative radiation approaches. His work spans multiple cancer types including lung cancer, head and neck cancers, breast cancer, and gynecologic malignancies. He has developed expertise in radiation pneumonitis, radiation recall phenomena, and the integration of novel agents like PARP inhibitors with radiation therapy. His research often addresses both clinical applications and healthcare policy aspects of radiation oncology. Analysis of Dr. Laird's publication history reveals a strong focus on gynecologic cancers (particularly ovarian, endometrial, cervical, vaginal, and vulvar cancers), head and neck malignancies, and small cell lung cancer. His work bridges basic science with clinical applications, particularly in the areas of radiation toxicity, novel combination therapies, and healthcare economics in radiation oncology. A notable trend in his research is the exploration of molecular imaging techniques to monitor therapeutic efficacy, as well as investigations into the relationship between radiation therapy and systemic treatments. Inducted into Alpha Omega Alpha honor society during medical school Named highest performing student in preclinical curriculum at NYU School of Medicine While specific details about his advising activities are not provided in the source material, Dr. Laird served as Chief Resident for the 2022-2023 academic year at Yale, indicating leadership in resident education. His research collaborations include frequent co-authors such as Melissa Rasar Young, MD, PhD; James B. Yu, MD; Jonathan Leventhal, MD; Shari Damast, MD; and Yi An, MD. These collaborations span multiple aspects of radiation oncology including gynecologic cancers, head and neck cancers, and healthcare policy. Dr. Laird is part of the Therapeutic Radiology department at Yale School of Medicine, which includes the Smilow Cancer Hospital, Yale Gamma Knife Center, and multiple satellite cancer care centers. His work contributes to the department's comprehensive approach to cancer treatment, combining clinical care with research innovation.
Daniel George, MSc, PhD is a Professor in both the Department of Humanities and the Department of Public Health Sciences at Penn State College of Medicine. With an active research career spanning from 2006 to the present, he has published 145 research outputs with an h-index of 25 and over 2,000 citations. His work has earned him recognition including the Dean's Award for Excellence in Teaching in 2022. Institution: Penn State College of Medicine Departments: Humanities and Public Health Sciences Research Output: 145 publications (2006-2025) Citations: 2,097 h-index: 25 Dr. George's research spans medical humanities, public health, and community-based health initiatives. His work focuses on dementia research, Alzheimer's disease, health disparities, medical education, and community health programs. His research fingerprint shows strong connections to People with Dementia (100%), Alzheimer's Disease (89%), Medical Center operations (85%), Farmers' Markets (81%), Penn State (81%), Medical Students (77%), Dementia (70%), and Community Gardens (66%). This unique combination of interests reflects his interdisciplinary approach that bridges clinical medicine with community engagement and humanities perspectives. Analysis of his recent publications (2023-2025) reveals a strong trend toward community-based health interventions, medical humanities applications, and health disparities research. His work increasingly integrates digital health approaches with traditional community settings, as seen in his research on gamified applications in nature-based settings. He also maintains a strong focus on neurological conditions, particularly dementia and Parkinson's disease, often exploring innovative educational and narrative approaches to these conditions. Dean's Award for Excellence in Teaching (2022) Dr. George has been actively involved in medical education, particularly in developing innovative approaches to teaching medical humanities and public health concepts. His recent work on student-led refugee initiatives demonstrates his commitment to addressing health disparities through community-embedded service learning. His research on language barriers in healthcare and the impact of graphic memoirs on patient understanding shows his interest in communication approaches that bridge cultural and cognitive gaps in healthcare settings. He appears to collaborate extensively across departments at Penn State, working with colleagues in clinical medicine, public health, and basic science departments. His work with community-based initiatives like farmers' markets and community gardens suggests strong community engagement beyond the traditional academic setting, focusing on practical applications of public health research to improve community health outcomes in Central Pennsylvania.
Laura Forker is an Honorary Senior Lecturer in the Division of Cancer Sciences at the University of Manchester. Her research focuses on tumor hypoxia, soft tissue sarcoma, and biomarker development for cancer therapy. She contributes to the Manchester Cancer Research Centre, addressing UN Sustainable Development Goals related to health and well-being. Her work includes translational research on hypoxia markers like CAIX and gene signatures for predicting treatment outcomes. Key projects involve developing clinically applicable biomarkers to improve radiotherapy efficacy and understanding tumor microenvironments. Collaborations include the UK VorteX-Biobank cohort study and projects funded by grants measuring tumor radioresistance (2022–2026).
Oliver Hanemann is Professor and Chair in Clinical Neurobiology at Manchester Metropolitan University's Peninsula Medical School and Neurology Consultant at University Hospitals Plymouth NHS Trust. His research bridges clinical and basic neuroscience with focus on brain tumours, Parkinson's disease mechanisms, and neuroimaging applications. Research encompasses: Molecular pathways in meningioma and schwannoma Neurodegenerative disease mechanisms Clinical applications of neuroimaging Recent publications highlight therapeutic targeting of tumour microenvironments and symptom management in motor neuron diseases. Current work includes developing novel therapeutic approaches for NF2-related tumours. Directs the Brain Tumour Centre of Excellence with approximately 30 researchers. Previously served as Associate Dean for Research (2015-2017) and Institute Director for Translational Medicine.
